Skip to main content
CJC-1295 Prescribed

CJC-1295 Studies and Source List

Each numbered mark lets you reach a source below. The main phase-1 human CJC-1295 trials are [1], [2], and [16].

Those papers studied blood levels and hormone bursts. The mouse work is at [3].

Blood-protein work is at [4]. A lab check of one seized sample is at [5], but it can't vouch for other products.

Papers [6], [7], [8], [9], and [10] explain related body messages. A trial of another drug in the same broad group is [11].

The WADA sports ban is [12]. FDA's 503A paper on drugs made specially by pharmacies is [13]; the public CJC-1295 account of the phase-2 heart event is [14].

The numbered marks lead to the papers below. FDA files and the sports ban are here too.

Which phase-1 sources studied people first?

Reference [1] is Teichman's 2006 one-dose trial. Reference [16] is his 2006 repeat-dose work.

Both studied CJC-1295 with DAC in healthy adults. Reference [2] is Ionescu's 2006 linked paper.

It counted growth-hormone bursts. These three papers make up the published phase-1 human record.

Which sources studied mice and blood proteins?

Reference [3] is Alba's 2006 mouse study. Reference [4] is Sackmann-Sala's 2009 blood-protein study.

Reference [5] is Henninge's 2010 check of one seized sample. Reference [6] is Frohman's 1989 paper.

That paper names DPP-IV, a blood protein that breaks down the body message 1-29. These sources show the compound's form and how the body breaks it down.

Which source looked at deep sleep?

Reference [9] is Steiger's 1992 study. Healthy men received the natural message through the nose.

The paper found more deep sleep. It wasn't a direct study of this compound.

Which sources cover rules and safety?

Reference [12] is WADA's 2025 banned list. Reference [13] is FDA's 2023 pharmacy paper.

Reference [14] is aidsmap's 2006 report on the ConjuChem trial, called CL-2002. It tells why the trial stopped.

That is news, not a trial paper. Use it only to trace the stop.

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  2. Ionescu M, Frohman LA. Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. ↗
  3. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. ↗
  4. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. ↗
  5. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. ↗
  6. Frohman LA, Downs TR, Heimer EP, Felix AM. Degradation of human growth hormone-releasing factor (hGRF 1-29)-NH2 by various peptidases and DPP-IV-mediated inactivation. J Clin Invest. 1989;83(5):1533-1540. ↗
  7. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. ↗
  8. Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. Growth hormone-releasing peptide-6 (GHRP-6) stimulates growth hormone secretion synergistically with GHRH in normal subjects. J Clin Endocrinol Metab. 1990;70(4):975-982. ↗
  9. Steiger A, Guldner J, Hemmeter U, Rothe B, Wiedemann K, Holsboer F. Sleep-promoting effects of growth hormone-releasing hormone in normal men. Neuroendocrinology. 1992;56(4):566-573. ↗
  10. Frohman LA, Thominet JL, Webb CB, Vance ML, Uderman H, Rivier J, Vale W, Thorner MO. Pharmacokinetics of growth hormone releasing factor [GRF(1-29)NH2] in normal men. J Clin Invest. 1984;73(5):1304-1311. ↗
  11. Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials. J Clin Endocrinol Metab. 2010;95(9):4291-4304. ↗
  12. World Anti-Doping Agency. World Anti-Doping Code International Standard — Prohibited List 2025. WADA-AMA. ↗
  13. U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting — CJC-1295 bulk drug substance nomination. 2023. ↗
  14. Carter M. Lipodystrophy study halted after patient death. aidsmap (NAM news report on ConjuChem trial CL-2002). 2006. ↗
  15. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Growth hormone (GH) response to ipamorelin, a new pentapeptidic selective GH secretagogue, in healthy volunteers. Pharm Res. 1999;16(9):1412-1416. ↗
  16. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults — multi-dose arm. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  17. Teichman SL et al., subcutaneous administration route as described in the CJC-1295 phase-1 pharmacokinetic protocol — see reference [1]. ↗